Search

PTC Therapeutics Inc

Chiusa

SettoreSettore sanitario

72.75 3.84

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

67.72

Massimo

71.37

Metriche Chiave

By Trading Economics

Entrata

86M

83M

Vendite

88M

361M

P/E

Media del settore

7.597

57.371

EPS

0.92

Margine di Profitto

23.16

Dipendenti

991

EBITDA

198M

162M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+41.92% upside

Dividendi

By Acuity

Utili prossimi

3 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-205M

6.1B

Apertura precedente

68.91

Chiusura precedente

72.75

Notizie sul Sentiment di mercato

By Acuity

54%

46%

276 / 340 Classifica in Healthcare

PTC Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

21 ago 2026, 19:26 UTC

PTC Therapeutics shares are lower today, trading near the lower end of their one-month range amid a broader market rebound in safe-haven assets.

20 ago 2026, 20:02 UTC

PTC Therapeutics shares are lower amid significant downward pressure on biotechnology stocks. The stock remains below its 20-day moving average.

19 ago 2026, 19:46 UTC

News

PTC Therapeutics is acquiring the ST-920 gene therapy asset for $111 million, including potential milestone payments, as shares trade higher since Tuesday's close.

18 ago 2026, 19:36 UTC

PTC Therapeutics Inc shares are lower amid cautious market sentiment influenced by rising treasury yields and inflation concerns. No specific news was identified for the decline.

14 ago 2026, 19:46 UTC

PTC Therapeutics shares are lower, reflecting broader market sentiment after U.S. retail sales unexpectedly declined in July. The stock is below its 20-day moving average.

13 ago 2026, 19:36 UTC

News
Social Media

PTC Therapeutics announced the acquisition of ST-920 for $111 million. Shares are lower amid ongoing bearish trends, despite Wells Fargo's Overweight rating and $109 price target.

12 ago 2026, 23:51 UTC

Social Media
News

PTC Therapeutics acquires ST-920 gene therapy for $111 million, enhancing its rare disease portfolio. Shares are higher in after-market hours.

11 ago 2026, 19:46 UTC

PTC Therapeutics Inc is trading lower amid market adjustments following last Friday's weak jobs report and ahead of upcoming U.S. inflation data releases.

10 ago 2026, 19:46 UTC

PTC Therapeutics shares are higher today amid broader market uncertainty regarding the Federal Reserve's interest rate policy following last week's employment report.

7 ago 2026, 21:02 UTC

PTC Therapeutics Inc shares are lower in after-market hours, reversing a trend of higher finishes over the past five sessions. No specific news was identified.

6 ago 2026, 19:56 UTC

PTC Therapeutics Inc. is higher today, having reached a peak earlier in the session. No specific news was identified to explain the price action.

5 ago 2026, 19:26 UTC

News

PTC Therapeutics Inc. will participate in upcoming investor conferences. Shares are lower today, remaining near the lower end of their one-month range.

4 ago 2026, 20:07 UTC

PTC Therapeutics shares are higher today, buoyed by positive market sentiment amid a significant decline in crude oil prices.

3 ago 2026, 19:46 UTC

News

PTC Therapeutics reported second-quarter revenue of $360.52 million and raised its full-year outlook to $1.18 billion to $1.28 billion, with shares advancing today.

31 lug 2026, 21:01 UTC

PTC Therapeutics Inc shares rose in after-market trading, despite broader market concerns over inflation and interest rates amid rising crude oil prices.

30 lug 2026, 22:31 UTC

News

PTC Therapeutics raised its 2026 revenue guidance after reporting strong Q2 results, with EPS of $0.92 exceeding estimates. Shares are higher in after-market trading.

29 lug 2026, 18:26 UTC

PTC Therapeutics Inc shares are lower today, reflecting a broader decline. Market participants await the Federal Reserve's interest rate decision this afternoon.

28 lug 2026, 18:31 UTC

News

PTC Therapeutics shares are lower as analysts anticipate a 5.6% revenue decline in Q2, contrasting with last year's growth of 24.2%.

27 lug 2026, 20:06 UTC

PTC Therapeutics Inc shares are lower today amid broader market declines, influenced by falling oil prices and Treasury yields ahead of the Federal Reserve meeting.

22 lug 2026, 17:16 UTC

PTC Therapeutics shares are lower today, trading near the lower end of their one-month range amid rising crude oil prices affecting the broader market.

21 lug 2026, 18:01 UTC

PTC Therapeutics shares are higher today, reflecting positive market sentiment. The stock remains near the lower end of its one-month range.

20 lug 2026, 19:56 UTC

News

PTC Therapeutics shares are lower as Wells Fargo cuts price target to $93.00 from $95.00 while keeping an Overweight rating.

Confronto tra pari

Modifica del prezzo

PTC Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

41.92% in crescita

Previsioni per 12 mesi

Media 99.09 USD  41.92%

Alto 130 USD

Basso 70 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per PTC Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

11 ratings

9

Acquista

1

Mantieni

1

Vendi

Sentiment

By Acuity

276 / 340 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo PTC Therapeutics Inc

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
help-icon Live chat